Abstract:Imidazoline receptors historically referred to a family of nonadrenergic binding sites that recognize compounds with an imidazoline moiety, although this has proven to be an oversimplification. For example, none of the proposed endogenous ligands for imidazoline receptors contain an imidazoline moiety but they are diverse in their chemical structure. Three receptor subtypes (I1, I2, and I3) have been proposed and the understanding of each has seen differing progress over the decades. I1 receptors partially mediate the central hypotensive effects of clonidine-like drugs. Moxonidine and rilmenidine have better therapeutic profiles (fewer side effects) than clonidine as antihypertensive drugs, thought to be due to their higher I1/α2-adrenoceptor selectivity. Newer I1 receptor agonists such as LNP599 [3-chloro-2-methyl-phenyl)-(4-methyl-4,5-dihydro-3H-pyrrol-2-yl)-amine hydrochloride] have little to no activity on α2-adrenoceptors and demonstrate promising therapeutic potential for hypertension and metabolic syndrome. I2 receptors associate with several distinct proteins, but the identities of these proteins remain elusive. I2 receptor agonists have demonstrated various centrally mediated effects including antinociception and neuroprotection. A new I2 receptor agonist, CR4056 [2-phenyl-6-(1H-imidazol-1yl) quinazoline], demonstrated clear analgesic activity in a recently completed phase II clinical trial and holds great promise as a novel I2 receptor–based first-in-class nonopioid analgesic. The understanding of I3 receptors is relatively limited. Existing data suggest that I3 receptors may represent a binding site at the Kir6.2-subtype ATP-sensitive potassium channels in pancreatic β-cells and may be involved in insulin secretion. Despite the elusive nature of their molecular identities, recent progress on drug discovery targeting imidazoline receptors (I1 and I2) demonstrates the exciting potential of these compounds to elicit neuroprotection and to treat various disorders such as hypertension, metabolic syndrome, and chronic pain.

Imidazoline derivatives: a patent review (2006--present).

Imidazoline Derivatives: a Patent Review (2006 – Present)

Novel benzopyran derivatives and their therapeutic applications: a patent review (2009–2016)

Biological impacts of imidazoline derivatives

PDE1 inhibitors: a review of the recent patent literature (2008-present)

Therapeutic charisma of imidazo [2,1-b] [1,3,4]-thiadiazole analogues: a patent review

Acridine and its derivatives: a patent review (2009 - 2013).

From Bench to Bedside: What Do We Know about Imidazothiazole Derivatives So Far?

Nitroimidazole derivatives: a patent review of US 2014/0141084 A1.

Imidazoline Receptor System: The Past, the Present, and the Future

Therapeutic significance of quinolines: a patent review (2013-2015)

Development of drugs based on imidazole and benzimidazole bioactive heterocycles: recent advances and future directions

Quinazoline derivatives and hybrids: recent structures with potent bioactivity

Pyrazole Scaffold Synthesis, Functionalization, and Applications in Alzheimer’s Disease and Parkinson’s Disease Treatment (2011–2020)

Recent progress in the development of β2 adrenergic receptor agonists: a patent review (2015-2020)

Exploring the untapped pharmacological potential of imidazopyridazines

Exploring the reactivity of bicyclic α-iminophosphonates to access new imidazoline I2 receptor ligands

A review on recent developments of indole-containing antiviral agents

Imidazolidinones Derivatives As Pioneering Anticancer Agents: Unraveling Insights Through synthesis And Structure‐Activity Exploration

QSAR modelling: a therapeutic patent review 2010-present

An Overview of Naphthylimide as Specific Scaffold for New Drug Discovery